Subscribe To
BFRI / Biofrontera Inc. (BFRI) Reports Q2 Loss, Lags Revenue Estimates
BFRI News
By Zacks Investment Research
September 18, 2023
All You Need to Know About Biofrontera Inc. (BFRI) Rating Upgrade to Buy
Biofrontera Inc. (BFRI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might dri more_horizontal
By Seeking Alpha
August 11, 2023
Biofrontera Inc. (BFRI) Q2 2023 Earnings Call Transcript
Biofrontera Inc. (NASDAQ:BFRI ) Q2 2023 Earnings Conference Call August 11, 2023 8:30 AM ET Company Participants Tirth Patel - Investor Relations Herm more_horizontal
By Zacks Investment Research
August 11, 2023
Biofrontera Inc. (BFRI) Reports Q2 Loss, Lags Revenue Estimates
Biofrontera Inc. (BFRI) came out with a quarterly loss of $6.14 per share versus the Zacks Consensus Estimate of a loss of $5.14. This compares to los more_horizontal
By Zacks Investment Research
May 12, 2023
Biofrontera Inc. (BFRI) Reports Q1 Loss, Misses Revenue Estimates
Biofrontera Inc. (BFRI) came out with a quarterly loss of $0.22 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.08 pe more_horizontal
By Seeking Alpha
March 8, 2023
Biofrontera, Inc. (BFRI) Q4 2022 Earnings Call Transcript
Biofrontera, Inc. (NASDAQ:BFRI ) Q4 2022 Earnings Conference Call March 8, 2023 4:30 PM ET Company Participants Erica Monaco - CEO, COO, Treasurer & S more_horizontal
By Accesswire
February 15, 2023
Biofrontera, Inc. to Present at Third Annual Winter Wonderland – Best Ideas Virtual Investor Conference on February 21st – 24th, 2023
WOBURN, MA / ACCESSWIRE / February 15, 2023 / Biofrontera, Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of de more_horizontal